Christopher Weber, Ph.D., director, Global Science Initiatives, oversees efforts to advance the scientific agenda of the Alzheimer’s Association, a global leader in advancing Alzheimer’s research. With over 20 years of clinical research experience, Dr. Weber is responsible for communicating the global research landscape of Alzheimer’s and dementia, including the breadth and reach of the Association’s research programs, and the critical need for increased research funding from the public and private sectors.
Dr. Weber directs Association initiatives that convene leaders from across the field to develop, expand and increase the success rate of Alzheimer’s diagnostic tools and drugs to treat and prevent the disease. He manages the Alzheimer’s Association Research Roundtable, a platform that enables international scientific, industry and government leaders to overcome shared obstacles in Alzheimer’s science and drug development. He also oversees the Global Biomarker Standardization Consortium (GBSC), an initiative that unites key researchers and clinicians with industry, regulatory and government leaders to achieve consensus on the best ways to standardize and validate biomarker tests for use in clinical practices worldwide.
Previously, Dr. Weber served as a clinical scientist with MedAvante-ProPhase where he led global management of clinical trials in Alzheimer's, Parkinson's and sleep-related disorders. A noted expert in the field, Dr. Weber has given numerous guest lectures and has presented his work at leading dementia science conferences, including the Alzheimer's Association International Conference® (AAIC®) and the Clinical Trials on Alzheimer's Disease Conference (CTAD).
Dr. Weber received his doctorate in clinical psychology from the Illinois Institute of Technology. He holds a master’s degree in kinesiology from the University of Illinois at Chicago and a bachelor's degree in psychology from the University of Wisconsin-Green Bay.